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OBJECTIVE: The participation of humans in clinical cardiology trials remains essential, but little is known regarding
participant perceptions of such studies. We examined the factors that motivated participation in such studies, as
well as those that led to participant frustration.
METHODS: Patients who had participated in hypertension and coronary arterial disease (phases II, III, and IV) clinical
trials were invited to answer a questionnaire. They were divided into two groups: Group I, which included
participants in placebo-controlled clinical trials after randomization, and Group II, which included participants in
clinical trials in which the tested treatment was compared to another drug after randomization and in which a
placebo was used in the washout period.
RESULTS: Eighty patients (47 patients in Group I and 33 patients in Group II) with different socio-demographic
characteristics were interviewed. Approximately 60% of the patients were motivated to participate in the trial
with the expectation of personal benefit. Nine participants (11.2%) expressed the desire to withdraw, which was
due to their perception of risk during the testing in the clinical trial (Group I) and to the necessity of repeated
returns to the institution (Group II). However, the patients did not withdraw due to fear of termination of hospital
treatment.
CONCLUSIONS: Although this study had a small patient sample, the possibility of receiving a benefit from the new
tested treatment was consistently reported as a motivation to participate in the trials.
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INTRODUCTION
Clinical research is responsible for current scientific
progress in the medical field, and the participation of
human patients is vital for the confirmation of new
therapeutic strategies.
Despite the efforts to ensure ethical rigor in research over
the past 60 years, ethical concerns have been an area of
concern to both researchers and government agencies, as
studies may involve the participation of potentially vulner-
able populations, especially in developing countries. Ethical
issues are evoked in such studies, as the study investigators
or sponsors are from developed countries, and the clinical
trials are often conducted in developing nations.
Study participants are vulnerable due to their poor
education level, unfamiliarity with scientific jargon, pov-
erty, and general lack of access to health care services (1).
Individuals with reduced autonomy, that is, those who are
vulnerable, must be protected so that they are not used only
as objects with which to conduct research and to aid in
scientific development (2).
Although participant autonomy is facilitated by the use of
an informed consent form in accordance with the Helsinki
Declaration, and, in Brazil, with Resolution 196/96 (3),
many studies have questioned the effectiveness of informed
consent documents as the common clarification method
used in clinical trials (4).
Such concern has arisen because many patients are
incapable of understanding the details in the document
presented to them (5) and often consent as a result of the
socioeconomic conditions under which they live and the
role that clinical trials play in their search for solutions to
health problems (6). Under these circumstances, partici-
pants may become frustrated due to a lack of understanding
of the actual role of a trial in which they have consented to
participate.
Studies have shown that the decision to participate in a
clinical trial is mainly motivated by altruism, that is, the
possibility of helping other people and science (7-9), as well
as by the desire for personal benefits, such as access to better
care or treatment (10).
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Nevertheless, little is known regarding the factors that
motivate participation in cardiology clinical trials focused on
heart failure (11,12). This study was conducted to evaluate
the factors that motivate participation in cardiology clinical
trials, as well as those leading to participant frustration.
METHODS
The present study was a descriptive, exploratory, and
quantitative study conducted in a public hospital specializ-
ing in cardiology. The study protocol was approved by the
Universidade de Sa˜o Paulo Hospital das Clı´nicas Ethics
Committee (reference number 1223/2005) on January 26,
2006, in accordance with the National Ethics Committee of
the Brazilian Ministry of Health (3).
The following were established as inclusion criteria: age
between 20 and 80 years; participation in phase II, III, or IV
clinical trials for drug testing that were conducted in
outpatient units from 2002 to 2006; placebo usage in the
washout phase or that was compared to the tested drug;
randomization into the clinical trial and consent to
participate. Individuals who did not have the ability to
remember their participation in the selected clinical trials
and/or did not agree to participate in this study were
excluded. Two groups were then formed: Group I,
comprising patients who had participated in placebo-
controlled trials after randomization, and Group II, com-
prising patients who had participated in clinical trials in
which the tested drug was compared to another drug after
randomization and in which the placebo was only adminis-
tered during the washout period. The participants in both
groups had the same clinical profiles, had chronic coronary
arterial disease, and had been followed as outpatients at the
institution. Some of these trials were published with all
patients here enrolled (13,14) and other were part of the
casuistic of the final trial (15).
Data were obtained by consulting patient ambulatory
records and by conducting an interview with patients via a
questionnaire containing 29 items that had been previously
designed and developed after considering all of the items on
the consent form necessitated by Resolution 196/96.
The questionnaire comprised two parts. The first part
aimed to collect identifying and demographic information
of the participants, such as name, hospital registration
number, age, gender, marital status, occupation, time of
follow-up at the institution, study in which he/she
participated and whether he/she completed the study. In
addition to general participant characteristics, this part of
the questionnaire evaluated education according to the
following levels: 1) elementary school, 2) secondary school
and 3) college. This evaluation considered whether each of
these levels had been completed.
The second part of the questionnaire consisted of open
and multiple-choice questions concerning participation in
the clinical trial. It began with questions related to the
invitation and motivation for participation (Why did you
choose to accept the invitation to participate in the study?;
five answer choices: a) for the sake of science, b) for your
own benefit, c) because the doctor assisting you asked you
to do so, d) because the doctor said it would be good for you
and e) for fear of not being given care or missing a treatment
opportunity due to the fact that the study took place at a
public hospital, or due to other reasons).
In the questionnaire, there were yes/no questions
concerning information that must be included in a consent
form, such as the importance of the study in which one was
invited to participate, risks and inconveniences, the exis-
tence of other therapies, information confidentiality,
expense refunds, compensation in the case of occasional
damage or problems, the need to read the consent form
before signing it, discussion about the consent document
with the researcher, confirmation of comprehension of the
information in the document and confirmation of compre-
hension of the word placebo.
Next, the questionnaire asked whether the participants
had considered withdrawing from the study, with yes or no
as possible answers. If the answer was affirmative, they
were asked for their reason and to state why the researcher
had not been informed, as all of the participants did
complete the study. Finally, we asked the participants, in an
open-answer format, what it meant for them to participate
in a clinical trial. All questionnaires were answered by the
patients themselves without any influence but with the help,
when necessary, of one investigator. The same investigator
aided all participants who required help.
Casuistic: Of the 106 participants selected for the inter-
view, two had died prior to the interview, eight were
excluded, two refused to participate, five did not come on
the scheduled interview date, and nine were unable to be
reached. Overall, 80 participants comprised the study
sample of 60 males (75.0%) and 20 females (25.0%). Of
those participants, 47 were in Group I (mean age 58.3 years),
and 33 were in Group II (mean age 59.4 years). All
participants were interviewed during the second half of
2006. The socio-demographic characteristics of all partici-
pants are shown in Table 1.
Table 1 - Socio-demographic characteristics of the study
sample.
Characteristics Group p Test
I II Total
n % n % n %
Gender
Female 12 25.5 8 24.2 20 25.0 0.896 C
Male 35 74.4 25 75.8 60 75.0
Education
0-7 yr 32 68.0 19 57.6 51 63.8 0.606 L
8-10 yr 5 10.6 4 12.1 9 11.2
11-14 yr 5 10.6 7 21.2 12 15.0
15 + yr 5 10.6 3 9.1 8 10.0
Marital status
With a partner 40 85.1 24 72.7 64 80.0 0.180 C
Without a
partner
7 14.9 9 27.3 16 20.0
Employment
activity
No 19 40.4 23 69.7 42 52.5 0.010 C
Yes 28 59.6 10 30.3 38 47.5
Employment
status
Onsickleave 1 2.1 0 0 1 1.2
Retired 12 25.5 18 54.5 30 37.5 0.02
Homemaker 6 12.8 5 15.2 11 13.8 V
Working 28 59.6 10 30.3 38 47.5
C = chi-square test; L = Likelihood Ratio Test; V = Likelihood maximum
test.
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Statistical analysis
The quantitative variables were analyzed by the determi-
nation of means and standard deviations. The classificatory
variables are presented in tables with absolute (n) and
relative (%) frequencies.
To evaluate whether there was an association between the
questions of interest, the Student’s t test, the chi-square test,
the likelihood ratio test or Fisher’s exact test was used when
applicable. Statistical analyses were performed using SPSS
Version 15.0 (SPSS Inc., EUA), and the level for significance
was set at p,0.05.
Qualitative analysis
The content analysis methodological framework was used
to analyze the descriptive data obtained by means of the
open questions (16).
Initially, pre-analysis, which consisted of the content
organization phase and was aimed at systematizing ideas,
was conducted. Next, the texts that essentially involved the
operation for data categorization was explored. Finally, the
data were analyzed and interpreted.
RESULTS
In both groups, most of the participants were illiterate or
had an incomplete elementary school education (63.8%), thus
characterizing the overall sample as having a poor education
level. Sixty-four (80.0%) participants had a partner and were
either married or had a common-law relationship.
Regarding employment, half of the participants (51.3%)
did not have a formal job, with 37.5% retired and 13.8%
performing household activities.
When the participants were asked about their reason for
participating in a clinical trial, 53 subjects (66.2%) in the
combined groups cited the personal benefit expected as the
primary reason, followed by the sake of science 34 subjects
(42.5%) (Table 2).
It was also found that 25.0% of the participants
participated in the clinical trials due to their doctor’s
request or to recommendations to participate in the clinical
trial, indicating the influence of professionals in the
decision-making process. Other individuals participated in
the trial because it was conducted at a public hospital
(10.0%) and because they feared no longer being given care
at the institution (3.8%) if they refused. Other cited reasons,
which represented 6.2% of the responses, were related to the
possibility of clinical tests that would not be available
during routine hospital care and to the influence of their
participation on the care received.
Nine patients (11.2%) reported the desire to withdraw
from the clinical trial (Table 3), but they did not inform the
investigator and completed the trial.
The main reason that led individuals from Group I (6.4%)
to consider withdrawing was the risk involved in certain
tests during the trial. In Group II, the main cited reason for
considering withdrawal was the frequency of medical
consultations required (6.0%).
The main reason reported by the participants for not
having interrupted their participation in the clinical trial
was fear of being prevented from receiving care at the
institution and discontinuation of their treatment (5%).
Additionally, it was found that the attempt to find a
treatment to improve their heart condition led the partici-
pants to not withdraw from the study despite their
dissatisfaction (2.5%).
DISCUSSION
Clinical research with pharmaceutical industry fund in
Brazil is still a relatively new area of concern, and it was only
in 1996 that guidelines and regulating standards for studies
involving humans were approved (3). Consequently, the
number of clinical studies sponsored by pharmaceutical
companies increased (particularly in cardiology), which was
Table 2 - Factors associated with the decision to participate in the clinical trial.
Reasons Group p Test*
I II Total
n % n % n %
For the sake of science
No
26 55.3 20 60.6 46 57.5
0.638 C
Yes 21 44.7 13 39.4 34 42.5
For your own benefit
No 17 36.2 10 30.3 27 33.8 0.585 C
Yes 30 63.8 23 69.7 53 66.2
Because the doctor assisting you asked you to
No 42 89.4 30 90.9 72 90.0 1.000 F
Yes 5 10.6 3 9.1 8 10.0
Because the doctor assisting you said it would be good for you
No 39 83.0 29 87.9 68 85.0 0.752 F
Yes 8 17.0 4 12.1 12 15.0
For fear of not being cared for at the hospital
No 45 95.7 32 97.0 77 96.2 1.000 F
Yes 2 4.3 1 3.0 3 3.8
Because it was a public hospital
No 41 87.2 31 93.9 72 90.0 0.459 F
Yes 6 12.8 2 6.1 8 10.0
Others
Na˜o 44 93.6 31 93.9 75 93.8 1.000 F
Yes 3 6.4 2 6.1 5 6.2
C = chi-square test; F = Fischer’s exact test.
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mainly due to the prevalence of diseases and large popu-
lation found in developing countries, easy recruitment and
good clinical research centers (17).
This increasing number of clinical research has been a
source of concern because the participants in clinical trials in
these countries may be more vulnerable during the consent
process due to their socio-economic conditions, poor
education level and limited access to health care services
(18). All of these issues were observed in the present study.
Regarding the factors associated with the decision to
participate in these studies, the expectation of personal
benefit and altruism were the main motivating factors.
Our results are similar to those of an Israeli study by
Yuval et al. (19) of 150 patients who participated in a
randomized and double-blinded clinical trial of a drug
developed for acute myocardial infarction. The study
revealed that 43% of the patients participated in the study
to receive better treatment, 12% expressed a desire for a
good follow-up, 35% reported a desire to help promote
medical research, 14% did not report a definite reason, and
8% reported being afraid to refuse to participate.
The expectation of personal benefit from participation in
the clinical trial is considered to be the major determinant of
successful patient recruitment (20).
However, when a participant erroneously believes that a
study can offer substantial clinical benefit, a therapeutic
misconception arises (21). In this situation, a patient who
understands that his/her doctor’s main goal is to find the
best treatment for his/her disease may overestimate the
personal therapeutic benefit from participating in the study.
Nevertheless, these trials can produce a large amount of
useful scientific knowledge and provide important benefits
to future patients even if they do not provide a direct benefit
to the current participants (22). Additionally, as an
investigator, a doctor makes treatment decisions based on
the specific design of each study (23).
However, many patients, as exemplified by this study,
also participate in clinical trials because they are motivated
by altruism, which corroborates the findings from other
studies, particularly oncological and prevention studies
(11,24). In ethical terms, such an attitude is ideal, as the
participant’s individual benefit cannot be guaranteed, nor is
that the objective of a clinical trial (24).
Burguess et al. (25) interviewed 250 patients who
participated in cardiovascular clinical trials and observed
that the main cited reasons for participation were the
possibility of access to medical care and a desire to
contribute to the advancement of science. Another point of
interest in our study is that 25% of the participants
participated in the clinical trial because of a doctor’s request
or recommendation. This information reflects the influence
that a doctor’s recommendations can have on a patient’s life
trajectory and on his/her decision-making process (26).
However, the fact that people tend to change their behavior
when they are the targets of interest and attention,
regardless of the specific nature of an intervention, must
also be considered. This phenomenon is known as the
Hawthorne effect (27), and in such situations, patients
become eager to please their doctors and make them feel
successful. Additionally, patients wish to participate so that
‘‘good’’ results can be achieved in the study.
Although the doctors who conducted the clinical trials
and enrolled the patients in this study were not always the
same as those who had cared for the patients in the
institution’s outpatient clinic, it is necessary to consider the
potential conflicts of interest that exist in studies sponsored
by pharmaceutical companies.
Nevertheless, secondary interests are not considered to be
negative per se, and the problem does not lie in whether
these interests can be defined as good or bad; rather, the
problem is that damage occurs when secondary interests
overlap and improperly influence, distort, or corrupt the
professional’s judgment with regard to the patient’s health,
the clinical trial, or education (28).
Another point of interest in our study was the dissatisfac-
tion expressed by nine individuals (11.2%) with regard to
continuing participation in the clinical trial that was not
expressed to the researcher during the course of the study.
It is possible that these omissions occurred due to an
asymmetry in the relationship between the researchers and
subjects, which is largely analogous to a doctor-patient
relationship. The doctor figure usually reflects an image of
power and knowledge; thus, questioning his/her judgement
may not facilitate the researcher-subject relationship (29).
The results of the present study also demonstrate that
even after patients read and discuss the consent form, which
is written in lay language, with the investigator, it may be
important to recheck during the follow-up which partici-
pants may have had the intention to abandon the trial but
feared to spontaneously express such an opinion, or even to
identify those individuals who did not understand the
consent form or the trial. We were not able to analyze the
consent forms from the trials we elected to evaluate, but all
of them were written according to the guideline approved
by our institutional ethics committee. The main reasons
leading the participants to consider withdrawing from the
clinical trials were the perception of risk in undergoing the
tests required by the trial (Group I) and the frequency of
required medical appointments (Group II). These findings
indicate that many patients signed the consent form and
agreed to participate in the study without actually under-
standing what was being asked of them. In these circum-
stances, studies evoke ethical issues, lead to great researcher
responsibility and may cause personal risks to research
subjects (30), as we have already seen (31).
Table 3 - Participants who thought about withdrawing from the clinical trial.
Did you think about withdrawing
from the study? Group p Test*
I II Total
n % n % n %
No 42 89.4 29 87.9 71 88.8 1.00 F
Yes 5 10.6 4 12.1 9 11.2
F = Fischer’s test.
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Additionally, it was found that most of the participants
did not withdraw from the study due to fear of discontinua-
tion of their treatment at the hospital. This finding is in stark
contrast to the principle of autonomy and leads us to reflect
on how free the participants in clinical trials in developing
countries really are to decide about remaining as a
participant in such trials when they depend on the care
provided by a public institution.
Potential study limitations
Our sample size may have been too small to achieve
accurate information regarding our question of interest.
Nevertheless, we think the study provides important
information.
In addition, this investigation, as a retrospective study, is
influenced by recall bias, even though recall ability was one
of the criteria used for participant exclusion. It is also possible
for a prospective study to present divergent findings.
The use of other interviewing techniques, and qualitative
techniques in particular, could certainly contribute to the
exploration of all of these concerns. Such techniques should
be employed in future studies addressing these issues.
CONCLUSION
The results of the present study indicated that the main
motivation for participating in a cardiology clinical trial was
the personal benefit expected by the participants in both
groups.
Although many of the patients confirmed their wish to
withdraw from the trial, their dependence on the care
provided by this medical center forced them to remain as
subjects in the study.
Additionally, the relative lack of understanding of the
study by some of the participants was evident, indicating
that the use of an informed consent form in developing
countries is a complex process that needs to be reviewed by
institutions participating in multi-center clinical trials.
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